Aurigene Pharmaceutical Services Launches New Biologics Facility in Hyderabad

• Aurigene Pharmaceutical Services, a subsidiary of Dr Reddy’s Laboratories, has opened a new biologics facility in Hyderabad’s Genome Valley.

• The 70,000ft² site is designed for process and analytical development and small-scale manufacturing for preclinical and early-phase clinical trials.

Aurigene Pharmaceutical Services launches new biologics facility in hyderabad. The 70,000ft² establishment is poised to deliver process and analytical development, alongside small-scale production of antibodies and various recombinant proteins, catering to preclinical and early-phase clinical trials.

Operational laboratories for process and analytical development are already functional, with manufacturing capacity slated for commissioning later in 2024. The facility prides itself on robust equipment, advanced control systems, and a competent workforce, ensuring a seamless scale-up to large-scale commercial operations adhering to current good manufacturing practice standards.

Aurigene’s new facility augments its existing discovery capabilities, focusing on a spectrum of recombinant proteins, including monoclonal antibodies, bi-specifics, immune-fusion molecules, antibody-drug conjugates, and other complex proteins. This expansion enables Aurigene to offer comprehensive services from discovery to large-scale commercial manufacturing, spread across three adjacent campuses.

The facility is also set to provide compliant and cost-effective cell lines, process development solutions, and analytical methods, targeting customers eager to expedite clinical development stages.

This launch aligns with Aurigene’s strategic plans to foster growth in both small molecule and biologics sectors. Aurigene CEO Akhil Ravi remarked, “The journey started a year back when we decided to invest in creating the facility. It is great to see the facility operational, and the addition of this capacity and capabilities shows our firm commitment to the continued expansion of our biologics business, building on 25 years of proven experience.”

Ravi further added, “The state-of-the-art facility will enable us to service our global customers efficiently and support the development of innovative medicine.” This statement underscores Aurigene’s dedication to enhancing its biologics business and its pledge to innovation in medicine.